Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 nov. 2017 07h30 HE | Source: Idera Pharmaceuticals, Inc.

U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
27 nov. 2017 16h01 HE | Source: Idera Pharmaceuticals, Inc.

Idera to Present at the 29th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
09 nov. 2017 07h30 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

- Available Translational Data Continue to Demonstrate Correlation between Proliferation and Clonal Expansion of T-Cells to Clinical Responses - - An additional 5th Unconfirmed RECIST v1.1 Response...
06 nov. 2017 16h02 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

– IMO 2125 Translational Data Update at SITC on November 11 –– Completes Public Offering, extends runway into second quarter 2019 – CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Idera...
26 oct. 2017 07h00 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced the pricing of its underwritten public...
24 oct. 2017 16h01 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides Corporate Governance Update

CAMBRIDGE, Mass. and EXTON, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
24 oct. 2017 16h01 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to $60...
08 sept. 2017 07h30 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
06 sept. 2017 13h00 HE | Source: Idera Pharmaceuticals, Inc.

Idera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T.

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
11 août 2017 11h00 HE | Source: Idera Pharmaceuticals, Inc.

Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...

Page précédente